The standard diagnostic evaluation of magnetic resonance imaging (MRI) in which radiologist use apparent diffusion coefficients (ADC) to determine risk of prostate cancer is called the Prostate Imaging Reporting and Data System (PIRADs). PI-RADs has limitations in terms of accuracy and inter-rater reliability. We sought to evaluate the diagnostic performance of a stretched-exponential model of diffusion-weighted MRI (DW-MRI) for prostate cancer (PCa) detection, which has the potential to assess signal decay in prostate tissue more accurately compared to other validated mono-exponential models.
INTRODUCTION AND OBJECTIVES:
The standard diagnostic evaluation of magnetic resonance imaging (MRI) in which radiologist use apparent diffusion coefficients (ADC) to determine risk of prostate cancer is called the Prostate Imaging Reporting and Data System (PIRADs). PI-RADs has limitations in terms of accuracy and inter-rater reliability. We sought to evaluate the diagnostic performance of a stretched-exponential model of diffusion-weighted MRI (DW-MRI) for prostate cancer (PCa) detection, which has the potential to assess signal decay in prostate tissue more accurately compared to other validated mono-exponential models.
METHODS: In this prospective study, 31 men with a total of 39 individual prostate lesions seen on MRI were consecutively enrolled and underwent MRI/ultrasound fusion prostate biopsies. Men with suspected PCa on multi-parametric MRI at 3-Tesla with b-values of 0, 50, 500, 1000, 1500 and 2000 s/mm2 were included. Clinical parameters were included to determine risk value of prostate cancer based on the Prostate Biopsy Collaborative Group (PBCG) risk calculator. ADC, a-values, PI-RADs, and PBCG were calculated using the standard mono-exponential DW-MRI model. ADC and a-values were calculated with the stretched-exponential DW-MRI model. The area under the receiver operating characteristic curve (AUC) was calculated to assess diagnostic performance.
RESULTS: Of 39 included individual lesions, PCa was confirmed for 13 lesions (1 lesion with Gleason core (GS) 6 and 12 lesions with GS greater than or equal to 7). Sample cohort demographics and clinical parameters included: a median age of 62 years, a median prostate-specific antigen (PSA) of 7.5 ng/mL, with 28% self-identifying as Black, 23% on active surveillance, and 23% having a positive history of PCa in the family. AUC values were: 0.75 for PIRADs, 0.64 for the PBCG algorithm, 0.84 for ADC, 0.71 for a, and 0.86 using the stretched-exponential model for ADC and a.
CONCLUSIONS: Stretched-exponential DW-MRI model provided excellent diagnostic performance for the detection of biopsyproven PCa. Performance was slightly superior to the standard monoexponential DW-MRI model as well as established clinical models using PI-RADs and PBCG. This motivates further investigation of these models for PCa assessment. (PCa) is increasing worldwide. There is no agreed protocol on how to monitor patients post focal therapy treatment however many institutions utilise multiparametric magnetic resonance imaging (mpMRI) to detect residual or recurrent PCa. The objective of this study is to determine the diagnostic accuracy of mpMRI to detect residual PCa following focal therapy with irreversible electroporation (IRE).
METHODS: Between February 2013 and September 2018, 170 patients consented and underwent primary IRE treatment. 102 of these patients were included for analysis after undergoing a follow-up mpMRI at 6 months and a transperineal template mapping biopsy at 12 months. PI-RADS v2 was used to report outfield region of interest (ROI) recurrence while a binary outcome (suspicious v nonsuspicious) was used for the infield ablative zone. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of mpMRI was calculated in patients with Gleason ! 3 þ 4, and Gleason ! 3 þ 3 with a maximum core length ! 4 mm on follow up biopsy. The diagnostic accuracy was calcuated for infield ROI, outfield ROI, as well as the whole gland.
RESULTS: Sensitivity, specificity, PPV and NPV of infield ROI was 40%, 98%, 67% and 94%, whilst outfield ROI was 58%, 93%, 69% and 90% respectively. For whole-gland this was 56%, 89%, 60% and 86%.
CONCLUSIONS: Our data shows that follow up mpMRI is able to rule out residual PCa in both the infield and outfield. However, given that 14% of residual PCa is missed by mpMRI, repeat prostate biopsies are still required in patients following focal therapy. Limitations of this study are the low incidence of recurrence in our cohort and the retrospective design of the study. . However, the phenomenon is poorly studied in humans. The aim of the study is to evaluate the effect of ADT on PSMA expression by repeated 68Ga-PSMA-11-PET/MRI scans.
METHODS: In this prospective, registered (NCT03313726) trial, men with newly diagnosed prostate cancer with high risk of metastasis underwent 68Ga-PSMA-11-PET/MRI immediately before and three times (within 8 weeks) after the initiation of ADT (Degarelix, 240mg). SUVmax measurements on primary tumour, lymph node and bone metastasis were performed.
RESULTS: The nine men included were all diagnosed with Gleason grade group 5 prostate cancer. Of those, three represented with locally advanced and six with metastatic disease. After ADT, all men reached castration level (s-testo<1.7nmol/L) within 10 days. In total, 16 prostate, 16 lymph node and 23 bone lesions were detected. In patient and lesion levels, a heterogeneous effect of ADT was observed. SUVmax trends in different lesions are demonstrated in Figure 1 . In 5 (31%) prostatic lesions an increasing trend in SUVmax was observed, Vol. 201, No. 4S, Supplement, Monday, May 6, 2019 THE JOURNAL OF UROLOGY Ò e1079
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